Genetic Signatures Cuts Losses 24% and Breaks into US Diagnostics Market

Genetic Signatures narrows losses and breaks into US market in 1H FY26

Genetic Signatures has reported Genetic Signatures 1H FY26 Results (ASX: GSS) showing a 23.8% improvement in underlying operating losses to $6.4m, whilst achieving first revenue recognition from the United States market. The Sydney-based molecular diagnostics company delivered revenue of $8.7m for the six months to 31 December 2025, up 2.4% on the prior corresponding period.

The half represents a transitional period for the company as it shifts toward geographic diversification. UK revenue contributed an additional $0.7m (up 11.5%), while two of three signed US customers are now live and generating revenue. The company closed the period with a cash position of $29.9m.

For pre-profit diagnostics companies, the dual outcome of international revenue growth combined with improving cash burn metrics represents progress on the path to commercial viability.

Breaking down the numbers

The Genetic Signatures 1H FY26 Results show revenue improved marginally despite gross margin compression. Gross profit declined 4.0% to $4.8m, with gross margin contracting from 58.8% to 55.7%. Management attributed the margin pressure to raw material cost increases for respiratory test kits.

Operating expenses declined as a percentage of revenue, contributing to the $2.0m improvement in underlying operating loss. The company also recognised $1.6m in R&D tax incentive income during the period.

Working capital improved by $4.3m during the period, with $2.4m relating to R&D activities and $1.9m from operational improvements. Cash used in operations was $5.2m, partially offset by a $4.4m R&D incentive receipt.

What is PCR diagnostic testing?

Polymerase Chain Reaction (PCR) testing is a molecular technique that detects specific genetic material from pathogens. The technology amplifies DNA or RNA sequences, enabling identification of bacteria, viruses, and other infectious agents in patient samples.

Genetic Signatures’ proprietary 3base technology simplifies complex genetic sequences during the PCR process. The system reduces the four-base genetic code to three bases, improving the accuracy and speed of pathogen detection whilst minimising the risk of human error in test interpretation.

The commercial advantage centres on three factors:

1. Reduced processing time compared to conventional PCR methods
2. Increased pathogen detection range within a single test
3. Lower error rates through simplified genetic sequence analysis

For investors, the technology represents a potential competitive advantage in infectious disease diagnostics, where speed and accuracy directly impact clinical outcomes and laboratory efficiency.

Geographic expansion gains traction

The company achieved its first US revenue recognition during 1H FY26, with two of three signed customers now operational. The third US customer is expected to commence operations in Q3. Management indicated this represents validation of the company’s ability to convert contracts into live revenue streams in a strategically important market.

UK and EMEA operations contributed $0.7m in additional revenue, representing 11.5% growth on the prior period. The company is focusing on infection control outcomes data to support further market penetration across the region.

• Australia: Revenue base maintained with steady testing volumes through the domestic flu season
• USA: First revenue recognised; two customers live; third customer expected to go live in Q3
• UK/EMEA: Revenue increased by $0.7m (11.5%); company pursuing additional distribution partnerships

The US market entry represents a strategic inflection point for Genetic Signatures. The ability to convert signed contracts into operational customers generating revenue de-risks the international expansion thesis and demonstrates commercial traction beyond the Australian home market.

Leadership transition underway

The company announced a CEO transition during the period, with key appointments including:

• Maria Halasz appointed as incoming Chief Executive Officer
• Anne Lockwood appointed Interim Managing Director
• Susanne Pedersen appointed Chief Technology Officer

The leadership refresh coincides with the company’s strategic review period and signals potential operational repositioning as the business scales internationally.

What’s next for Genetic Signatures?

Management outlined four priority areas for the second half of FY26, with cost optimisation measures expected to flow through in FY27:

1. Revenue: Maintain steady Australian operations whilst prioritising growth in US and EMEA markets to build geographic diversification
2. Product: Increase awareness of 3base technology advantages; identify new product opportunities and automation capabilities
3. Financial discipline: Detailed operating cost review underway with savings targeted for realisation across FY27
4. Capital management: Advisors appointed to review strategic options for delivering shareholder value

The appointment of advisors to review strategic options represents a notable development. This process could result in partnership arrangements, merger and acquisition activity, or capital structure optimisation as the company seeks to balance growth investment with path to profitability.

The company intends to maintain its cash position at levels that enable targeted commercial investment whilst supporting ongoing innovation in assay development, workflow optimisation, instrumentation, and software capabilities.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements delivered straight to your inbox the moment they drop.